Next generation vaccines for diseases of global health importance
Curevo Vaccine is a clinical-stage biotechnology company, focused on bringing new generation adjuvanted subunit vaccines to market. We combine excellence in protein and adjuvant biology to create vaccines of global importance.
We are located in Seattle, WA.
Our lead vaccine candidate CRV-101 is being investigated to provide data on safety, tolerability, immunogenicity and effectiveness to support an indication for prevention of Shingles in older adults. CRV-101 has been evaluated in a Phase 1 clinical trial in healthy adults. Investigations are under development to evaluate CRV-101 in immunocompromised children for the indication of prevention of chickenpox.
Partnerships are powerful. Consider partnering with Curevo.
Contact us through the form below to find out how.